Anti-body Coupled T Receptor Therapy Market to Rear Excessive Growth During 2016 – 2024

Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in which body’s own immune response is utilized to act on cancerous cell. Anti-body coupled T receptor therapy utilizes T cells from body, engineered it to express specific T cell receptor, multiplying it in lab and then administering it along with targeting antibodies. The advantage in this approach is, that these T cells do not attack normal antigens from blood circulation but attack only antigens attached to the cancerous cells. This is possible as tumor specific monoclonal antibodies are given together with ACTR T cells. ACTR therapy is cost effective as it can be used in various cancer therapy. Also, greater therapeutic benefit with minimum side effects can be possible by adjusting the amount of targeting antibody which is essential for activation of the ACTR T cells.

Get The Holistic SAMPLE With Research Methodology: https://www.coherentmarketinsights.com/insight/request-sample/1600

Rising incidence of cancer and new products to be launched in future to drive the market for anti-body coupled T receptor therapy market.

According to World Health Organization (WHO), cancer is one of the leading non-communicable disease and second leading cause of death globally. As reported by International Agency for Research on Cancer (IARC) in 2012, there were 14.1 million new cases, 8.8 million deaths and 32.6 million people living with cancer worldwide. As per 2017 report by Leukemia and Lymphoma Society, U.S. alone is expected to have prevalence of 8,16,834 and 80,500 annual new cases of lymphoma. Therefore, such high number of cancer patient would propel the anti-body coupled T receptor therapy market.

ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead Lifescience, Inc.) has side effects such as cytokine release syndrome, and neurological toxicity as discussed in their respective product literatures and other studies. ACTR therapy being specific in its action do not produce such side effects. This advantage would drive the anti-body coupled T receptor therapy market in future. Also CAR-T therapy has application in specific type of cancer such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma whereas ACTR therapy has potential use even in solid tumorous cancer such as breast cancer, and neuroblastoma.

Click To Continue Reading On Anti-body Coupled T Receptor Therapy Market

You may be interested

Business

Hydrogen Vehicle Market Positive long-term growth outlook 2018-2025

Sayali Tribhuvan - June 24, 2018

Hydrogen Vehicle Market Report provides an analytical assessment of the prime challenges faced by this Market currently and in the coming years, which helps Market participants in…

Hashgraph Market New Research Highlights the Current Trends, Opportunities And Challenges For Industry
Information Technology and Gadgets
Information Technology and Gadgets

Hashgraph Market New Research Highlights the Current Trends, Opportunities And Challenges For Industry

Sayali Tribhuvan - June 23, 2018

Hashgraph Market Report provides an analytical assessment of the prime challenges faced by this industry currently and in the coming years, which helps market participants in understanding…

Speech Analytics Market Segmentation by Revenue, Present & Future Scenario To 2025
Information Technology and Gadgets
Information Technology and Gadgets

Speech Analytics Market Segmentation by Revenue, Present & Future Scenario To 2025

Sayali Tribhuvan - June 23, 2018

Speech Analytics Market Report provides an analytical assessment of the prime challenges faced by this industry currently and in the coming years, which helps market participants in…

Most from this category